- Home
- BLRX vs TPCS Comparison
BLRX vs TPCS Comparison
Compare BLRX & TPCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- TPCS
- Stock Information
- Founded
- BLRX 2003
- TPCS 1956
- Country
- BLRX Israel
- TPCS United States
- Employees
- BLRX N/A
- TPCS N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- TPCS Metal Fabrications
- Sector
- BLRX Health Care
- TPCS Industrials
- Exchange
- BLRX Nasdaq
- TPCS Nasdaq
- Market Cap
- BLRX 36.0M
- TPCS 32.1M
- IPO Year
- BLRX 2011
- TPCS N/A
- Fundamental
- Price
- BLRX $0.20
- TPCS $3.45
- Analyst Decision
- BLRX Strong Buy
- TPCS
- Analyst Count
- BLRX 2
- TPCS 0
- Target Price
- BLRX $5.50
- TPCS N/A
- AVG Volume (30 Days)
- BLRX 2.2M
- TPCS 23.8K
- Earning Date
- BLRX 11-25-2024
- TPCS 11-12-2024
- Dividend Yield
- BLRX N/A
- TPCS N/A
- EPS Growth
- BLRX N/A
- TPCS N/A
- EPS
- BLRX N/A
- TPCS N/A
- Revenue
- BLRX $21,991,000.00
- TPCS $32,205,714.00
- Revenue This Year
- BLRX N/A
- TPCS N/A
- Revenue Next Year
- BLRX N/A
- TPCS N/A
- P/E Ratio
- BLRX N/A
- TPCS N/A
- Revenue Growth
- BLRX N/A
- TPCS 1.51
- 52 Week Low
- BLRX $0.19
- TPCS $2.85
- 52 Week High
- BLRX $1.70
- TPCS $5.95
- Technical
- Relative Strength Index (RSI)
- BLRX 24.20
- TPCS 46.75
- Support Level
- BLRX $0.23
- TPCS $3.25
- Resistance Level
- BLRX $0.56
- TPCS $4.01
- Average True Range (ATR)
- BLRX 0.03
- TPCS 0.24
- MACD
- BLRX -0.00
- TPCS -0.02
- Stochastic Oscillator
- BLRX 7.26
- TPCS 26.32
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About TPCS TechPrecision Corporation Common stock
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.